Loading...
•
Jun 30, 2024
ORIC Pharmaceuticals Q2 2024 Earnings Report
ORIC Pharmaceuticals reported financial results and provided operational updates for Q2 2024.
Key Takeaways
ORIC Pharmaceuticals reported cash and investments of $308.5 million, which is expected to fund operating plan into late 2026. The company is advancing its pipeline with ORIC-114 and ORIC-944, and expanded its leadership team.
Initiated dosing of ORIC-944 in combinations with NUBEQA® and ERLEADA® in the ongoing Phase 1b trial for prostate cancer.
Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combination with NUBEQA® and ERLEADA®.
Expanded leadership team with the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs.
Cash and investments of $308.5 million expected to fund operating plan into late 2026.
Forward Guidance
ORIC Pharmaceuticals anticipates sharing further clinical updates in 2025 and expects cash and investments of $308.5 million to fund its operating plan into late 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...